

# Atrial Cardiopathy and Ischemic Stroke: A Mechanism Unveiled by Ultrasound

Anna Palmieri<sup>1</sup>, Caterina Kulyk<sup>1</sup>, Francesca Rebecca Vodret<sup>1</sup>, Alessio Pieroni<sup>1</sup>, Federica Viaro<sup>1</sup>, Manfred Kaps<sup>2</sup>, Claudio Baracchini<sup>1</sup>.

<sup>1</sup>Stroke Unit and Neurosonology Lab, University Hospital of Padua, Padua, Italy.

<sup>2</sup>Neurology Clinic, University Hospital of Giessen, Giessen, Germany.


## Background

Patients with cryptogenic stroke (CS) still receive an untargeted secondary prevention treatment. Atrial fibrillation (AF), which is considered one of the main disorders behind CS, is associated with left atrium derangements – collectively called **atrial cardiopathy** – which **could account by themselves for thrombogenesis and embolism in CS**.

This study aimed to investigate whether, in CS patients, atrial cardiopathy is related to AF detection, recurrent strokes, or to the presence of micro-embolic signals (MES) at trans-cranial Doppler (TCD), which are a surrogate marker for stroke risk.

## Subjects and Methods

We enrolled all consecutive CS patients, first retrospectively (Padua, 2015-2017), and later prospectively (Padua/Giessen, March-June 2018). We assessed the presence of atrial cardiopathy markers. Medical records were reviewed to detect new-onset AF and recurrent strokes.




## Results

### Characteristics of the overall study population (n=169)

#### Cerebrovascular risk factors and stroke characteristics (%)

Male sex	60%	Coronary Heart Disease	9%
Age; mean $\pm$ sd	68.4 $\pm$ 12.9	Peripheral Vasculopathy	3%
Carotid stenosis $\leq$ 50%	69%	CHA <sub>2</sub> DS <sub>2</sub> -VASc score; median (IQR)	5 (3-5)
Previous stroke	5%	NIHSS at admission; mean $\pm$ sd	10.0 $\pm$ 6.6
Hypertension	72%	NIHSS at discharge; mean $\pm$ sd	3.4 $\pm$ 4.3
Diabetes	16%	Systemic thrombolysis with r-tPA	65%
Dyslipidemia	38%	Endovascular treatment	29%
Smoking	20%	Combined treatment	18%

**Distribution of atrial cardiopathy markers**  
(% of patients with pathologic value)



### Retrospective cohort (n=130): atrial cardiopathy and AF detection

**Early AF detection (< 7 days): 18%**

[mean: 3.6 days]


**Late AF detection (> 30 days): 15.4%**

[mean: 8.6 months]

Follow-up duration: 17.0  $\pm$  10.8 months

**Independent predictors of late AF detection** at multivariate analysis:

- ESEA** at Holter ECG ( $p < 0.001$ )
- LAVI  $\geq 32 \text{ ml/m}^2$**  at echo ( $p = 0.003$ )




ROC curve for the predictive model: AUC 0.923; CI 95% 0.868-0.979 ( $p < 0.001$ )

### Retrospective cohort (n=130): atrial cardiopathy and recurrent stroke

**Annualized rate of stroke recurrence: 6%** ( $f\text{-up } 17.0 \pm 10.8 \text{ m}$ )

**Independent predictors of recurrent stroke** at multivariate analysis:

- ESEA: OR 8.8** (2.5-30.8,  $p = 0.001$ )
- LAVI  $\geq 32 \text{ mL/m}^2$ : OR 5.5** (1.0-32.1,  $p = 0.05$ )



Distribution of atrial cardiopathy markers


### Prospective cohort (n=39): atrial cardiopathy and MES at TCD monitoring

**1° TCD monitoring** (15.4  $\pm$  5.7 hours from onset):

**33% of patients had MES**  
[rate: 1.7  $\pm$  0.9 MES/h]

**2° TCD monitoring** (6.7  $\pm$  0.6 days from onset):


**20% of patients had MES**  
[rate: 1.1  $\pm$  0.4 MES/h]



**Independent predictors of MES at TCD monitoring** at multivariate analysis:

- Age: RR 1.2** (IC 95% 1.0-1.5)  $p = 0.02$
- LAD: RR 7.9** (IC 95% 2.1-30.3)  $p = 0.002$

ROC curve for prediction of MES by an **«Atrial cardiopathy score»** obtained by adding 1 point for every detected marker



AUC 0.979 (CI 95% 0.941-1.000)  $p < 0.001$

## Conclusions

Atrial cardiopathy markers are related to the presence of MES in the acute phase of stroke and represent a risk factor for AF and recurrent stroke.